Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
The IND amendment filing for Celltrion’s Phase 3 clinical trial of CT-P55 (a Cosentyx biosimilar candidate) in the U.S. was completed as the standard 60-day FDA review period elapsed without separate notification.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Approval of Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S.
- Filing Date & Fact Confirmation Date (Approval Date): Filing Date March 12, 2026 / Approval Date May 12, 2026 (Local Time)
- Regulatory Agency: U.S. Food and Drug Administration (FDA)
- Clinical Trial Phase: Global Phase 3
- Target Indication: Moderate to Severe Plaque Psoriasis
- Clinical Trial Title: A randomized, active-controlled, double-blind Phase 3 study to compare the efficacy and safety of CT-P55 versus Cosentyx in patients with moderate to severe plaque psoriasis
- Trial Registration Number: EU CT number 2024-513348-27-00
- Trial Scale & Duration: 153 patients / 56 weeks
- Trial Design: Randomized, active-controlled, double-blind
- Basis of Confirmation Date: Stated based on the passage of 60 days from the filing date in accordance with FDA regulations (MAPP 6030.9) regarding IND amendment review targets (FDA does not issue separate written approval notices).
- Investment Caution: Statistically, the final approval rate for clinical drug candidates is approximately 10%. Unforeseen results during trial or approval stages may lead to changes or cancellation of commercialization plans.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Clinical Trial Execution via Subsequent Regulatory Reports
This disclosure reflects the procedural completion of an IND amendment following the passage of 60 days under FDA guidelines rather than a written approval issuance, making it important to monitor upcoming official filings for trial progress. Verifying future progress reports ensures that trial activities align with the updated protocol following the procedural lapse of the review timeframe. Updates regarding trial execution can be tracked through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) under the ‘Ongoing Research and Development Activities’ section or through future regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
